Peripheral Arterial Disease Clinical Trial
Official title:
a Prospective, Multicenter, Controlled Trial Evaluating the Implant of a Drug Eluting Stent (XIENCE PRIME, Abbott Vascular) in the Critically Ischemic Lower Leg
The objective of this clinical evaluation is to evaluate the immediate and long term (up to 12 months) outcome of the XIENCE PRIME Everolimus Eluting Coronary Stent System (Abbott Vascular) in a controlled prospective investigation for the treatment of patients with critical limb ischemia due to the presence of lesions between 3cm and 10cm in length at the level of the below the knee arteries. Specifically the trial aims to illicit angiographic and ultrasound patency, clinical improvement, and adverse events associated with the use of this stent. The trial design is single armed, prospective, controlled trial run over 12 months of follow-up.
The aim of this research is to evaluate the immediate and long term outcome of the XIENCE
PRIME EverolimusEluting Coronary Stent System in a prospective investigation for the
treatment of patients with critical limb ischemia due to the presence of lesions between 3cm
and 10cm in length at the level of the below the knee arteries.
The research question is "Dose the use of an Everolimus coated stent in long tibial artery
occlusions, between 3 and 10cm offer superior patency at 12 months compared to a historical
cohort of bare metal stents in similar lesions?" Our hypothesis is that the use of
everolimus coated stents in tibial artery occlusions between 3 and 10cm will result in lower
binary restenosis than was historically found in equivalent but non-drugcoated bare metal
stents.
Currently, there is evidence that angioplasty and drug eluting stents can be used as a
therapy for patients with critical limb ischemia due to occlusive infrapopliteal disease.
The XIENCE PRIME™ Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS or XIENCE
PRIME stent system) is manufactured by Abbott. It is a device/drug combination product
consisting of the CobaltChromium MULTILINK VISION 8 Coronary Stent System coated with a
formulation containing everolimus, the active ingredient, embedded in a nonerodible polymer.
The XIENCE PRIME Everolimus Eluting Coronary Stent is coated with everolimus (active
ingredient), embedded in a nonerodible polymer (inactive ingredient). Everolimus is the
active pharmaceutical ingredient in the XIENCE PRIME stent. It is a novel semisynthetic
macrolide immunosuppressant, synthesized by chemical modification of rapamycin (sirolimus).
The everolimus chemical name is 40O(2hydroxyethyl) rapamycin.
The XIENCE PRIME stent contains inactive ingredients including poly n-butyl methacrylate
(PBMA), a polymer that adheres to the stent and drug coating, and PVDFHFP, which is
comprised of vinylidene fluoride and hexafluoropropylene monomers as the drug matrix layer
containing everolimus. PBMA is a homopolymer with a molecular weight (Mw) of 264,000 to
376,000 dalton. PVDFHFP is a nonerodible semicrystalline random copolymer with a molecular
weight (Mw) of 254,000 to 293,000 dalton. The drug matrix copolymer is mixed with everolimus
(83%/17% w/w polymer/everolimus ratio) and applied to the entire PBMA coated stent surface.
The drug load is 100 μg/cm2 for all product sizes. No top-coat layer is used.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |